Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes

    ... for patients with MDS, increasing time to progression to acute myelogenous leukemia and improving overall response rates. Although ...

    Research Article last updated 11/05/2012 - 9:58am.

  2. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in ...

    Research Article last updated 07/31/2012 - 2:02pm.

  3. Safety and efficacy of azacitidine in myelodysplastic syndromes.

    ... in overall survival and delaying time to progression to acute myelogenous leukemia . The recommended dosage of azacitidine is 75 mg/m(2) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... blood cytopenias and a marked propensity to progress to acute myelogenous leukemia . With 40,000-76,000 new cases per year in the USA, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Myelodysplastic syndromes: the role of the immune system in pathogenesis

    ... risk of infection, and variable risk of progression to acute myelogenous leukemia . Several theories of MDS pathogenesis exist, with ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib ...

    Research Article last updated 08/04/2014 - 8:28am.

  8. Myelodysplastic Syndromes (MDS)

    ... others are more severe, and carry a high risk of becoming acute myelogenous leukemia (AML). The subtype you have, and the severity of your ...

    Page last updated 02/27/2017 - 7:36am.

  9. Types

    ... Excess Blasts in Transmission) Note: Now called AML ( acute myelogenous leukemia ) < 5 5 - 20 ...

    Topic section last updated 11/14/2016 - 1:11pm.

  10. Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

    ... orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) orMyelodysplastic Syndrome (MDS). ...

    Clinical Trial last updated 04/27/2016 - 3:39pm.